HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

(4- (5- (4- fluorophenyl)- 2- methylsulfanyl- 3H- imidazol- 4- yl)pyridin- 2- yl)- (1- phenylethyl)amine

a p38 mitogen-activated protein kinase inhibitor; structure in first source

Also Known As:

ML 3403; ML-3403; ML3403

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - (4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine: 3
  - Pyridines: 88
    - (4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine: 3

Experts

1.	Laufer, Stefan: 2 articles (03/2014 - 01/2012)
2.	Campos, Maria M: 1 article (03/2014)
3.	Koch, Diana A: 1 article (03/2014)
4.	Leite, Carlos E: 1 article (03/2014)
5.	Morrone, Fernanda B: 1 article (03/2014)
6.	Nicoletti, Natália F: 1 article (03/2014)
7.	Silva, Rodrigo B M: 1 article (03/2014)
8.	de Souza, Alessandra H: 1 article (03/2014)
9.	Burnet, Michael: 1 article (01/2012)
10.	Cavazzoni, Emanuel: 1 article (01/2012)

Related Diseases

1.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 07/01/2010 - "This conference report highlights selected presentations on the novel thiopurine-based immunosuppressive agents B-0N and E-1 (both Giuliani SpA/Friedrich-Alexander-Universitaet Erlangen-Nuernberg); the investigation of ML-3403 (c-a-i-r biosciences GmbH), a p38 MAPK inhibitor for the treatment of chronic inflammatory disease; the development of ALV-003 (Alvine Pharmaceuticals Inc) for the treatment of celiac disease; efficacy studies of AST-120 in patients with irritable bowel syndrome; and a clinical trial evaluating linaclotide (Ironwood Pharmaceuticals Inc/Forest Laboratories Inc/Astellas Pharma Inc/Almirall Prodesfarma SA) withdrawal during chronic constipation therapy."
2.	Constipation 07/01/2010 - "This conference report highlights selected presentations on the novel thiopurine-based immunosuppressive agents B-0N and E-1 (both Giuliani SpA/Friedrich-Alexander-Universitaet Erlangen-Nuernberg); the investigation of ML-3403 (c-a-i-r biosciences GmbH), a p38 MAPK inhibitor for the treatment of chronic inflammatory disease; the development of ALV-003 (Alvine Pharmaceuticals Inc) for the treatment of celiac disease; efficacy studies of AST-120 in patients with irritable bowel syndrome; and a clinical trial evaluating linaclotide (Ironwood Pharmaceuticals Inc/Forest Laboratories Inc/Astellas Pharma Inc/Almirall Prodesfarma SA) withdrawal during chronic constipation therapy."
3.	Celiac Disease (Celiac Sprue) 07/01/2010 - "This conference report highlights selected presentations on the novel thiopurine-based immunosuppressive agents B-0N and E-1 (both Giuliani SpA/Friedrich-Alexander-Universitaet Erlangen-Nuernberg); the investigation of ML-3403 (c-a-i-r biosciences GmbH), a p38 MAPK inhibitor for the treatment of chronic inflammatory disease; the development of ALV-003 (Alvine Pharmaceuticals Inc) for the treatment of celiac disease; efficacy studies of AST-120 in patients with irritable bowel syndrome; and a clinical trial evaluating linaclotide (Ironwood Pharmaceuticals Inc/Forest Laboratories Inc/Astellas Pharma Inc/Almirall Prodesfarma SA) withdrawal during chronic constipation therapy."
4.	Arthritis (Polyarthritis) 03/01/2014 - "In the present study we compared the effects of the selective p38 inhibitor ML3403 and the dual p38-PDE4 inhibitor CBS-3595, on inflammatory and nociceptive parameters in a model of polyarthritis in rats. " 03/01/2014 - "Repeated CBS-3595 (3 mg/kg) or ML3403 (10 mg/kg) administration produced significant anti-inflammatory actions in the chronic arthritis model induced by CFA. " 03/01/2014 - "Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats."
5.	Stomach Neoplasms (Stomach Cancer) 01/15/2012 - "Administering mice with ML3403 and SB203580, potent and selective p38 MAPK inhibitors, attenuate the formation of neoplastic foci induced by intraperitoneal inoculation of gastric cancer cells. "

Related Drugs and Biologics

1.	p38 Mitogen-Activated Protein Kinases
2.	Immunosuppressive Agents (Immunosuppressants)
3.	linaclotide
4.	2-mercaptopurine
5.	AST 120
6.	CBS-3595
7.	Type 4 Cyclic Nucleotide Phosphodiesterases
8.	SB 203580

Related Therapies and Procedures

1.	Therapeutics